Regeneron’s [NASDAQ: REGN] COVID19 Antibody Lessens Hospitalization Risk

Regeneron Pharmaceuticals, Inc. [NASDAQ: REGN] disclosed that its COVID-19 antibody has shown positive results in the largest trial. The firm has revealed that its investigational REGEN-COV™ (casirivimab with imdevimab) has reduced the hospitalization risk by 70%. This is the greatest breakthrough in the development of vaccines to fight against the novel coronavirus which has affected people all around the world.

Shares of Regeneron Pharmaceuticals went up 2.01% as it gained +9.52 during the trading session of Monday. The firm has disclosed that it is planning to share the results of both trials with the authorities. REGN will continue the evaluation of its drug candidate in different settings. More than 25,000 people have participated in the trials as of March 2021.

REGEN-COV has reduced the risk of hospitalization and death in the outpatient setting. In the Phase III trial, REGEN-COV has met all the secondary endpoints. The firm is planning to request the authorities regarding the addition of a 1,200 mg dose to the U.S. EUA. The firm has disclosed that the only adverse effects the firm encountered were related to COVID-19.